NTLX.V NeuroThera Labs Inc.
- Market cap
- CAD 137M
- P/E
- -
- P/B
- 5.07x
- ROE
- -3,076.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jan 2026.
Is NTLX.V undervalued?
Graham numberThe Graham number of NeuroThera Labs Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NeuroThera Labs Inc. fundamental analysis
No fundamental analysis for NeuroThera Labs Inc. yet.
NeuroThera Labs Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NeuroThera Labs Inc.
Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. It also focuses on e-commerce operations, which sells hemp-based products. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The com…
Full company profileNeuroThera Labs Inc. financial statements
NeuroThera Labs Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 856K |
| Gross Profit | - | - | - | 506K | 631K |
| Operating Income | -150K | -79.8K | -78.1K | -176K | -4.15M |
| EBITDA | - | - | -78.1K | -176K | -4.03M |
| Net Income | -153K | -79.9K | -78.1K | -176K | -4.12M |
| EPS | -0.01 | 0.00 | 0.00 | -0.01 | -0.05 |
| Balance Sheet | |||||
| Total Assets | 1.37M | 1.28M | 911K | 746K | 3.03M |
| Total Liabilities | 17.6K | 9.15K | 30.8K | 108K | 2.39M |
| Shareholders' Equity | 1.35M | 1.27M | 880K | 638K | 134K |
| Cash & Short-term Investments | 1.36M | 1.28M | 910K | 745K | 1.70M |
| Cash Flow | |||||
| Operating Cash Flow | -110K | -80.9K | -52.6K | -97.1K | -1.66M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -110K | -80.9K | -52.6K | -97.1K | -1.66M |
| Ratios | |||||
| ROE | -11.3% | -6.3% | -8.9% | -27.6% | -3,076.9% |
| ROA | -11.1% | -6.2% | -8.6% | -23.6% | -135.9% |
| Net Profit Margin | - | - | - | - | -481.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NeuroThera Labs Inc. dividends
NeuroThera Labs Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:14 on Sep 2, 2026.
Who owns NeuroThera Labs Inc.
- Insiders 33.34%
- Institutions 0.00%
- Public & others 66.67%
- Shares outstanding 84.9M
- Free float 7.54M
NeuroThera Labs Inc. company profile
- Company name
- NeuroThera Labs Inc.
- Ticker
- NTLX.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Fiscal year end
- January
- Address
- 18 Shea Way, Newark, DE, United States, 19713
- Website
- neurothera.com
About NeuroThera Labs Inc.
Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder, and status epilepticus. It also focuses on e-commerce operations, which sells hemp-based products. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Newark, Delaware. Neurothera Labs Inc. is a subsidiary of SciSparc Ltd.
NeuroThera Labs Inc. management
3- Mr. Gabriel KabazoCFO & Corporate Secretary · born 1973
- Mr. Oz Adler CPAChief Executive Officer · born 1987
- Michal EfratyIR Manager